卵巢癌治疗手段有限，患者生存期短。研究人员开展了熊去氧胆酸（UDCA）对卵巢癌细胞作用的研究。结果发现，UDCA 可诱导癌细胞发生上皮 - 间质转化（EMT）等，且相关基因高表达与患者生存期短有关。该研究为卵巢癌治疗用药提供了警示。 在医学研究的广阔 ...

Ipsen has announced that its Iqirvo (elafibranor) tablets have been accepted by the Scottish Medicines Consortium (SMC) to ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg – and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD). NAFLD, the most prevalent liver disease, affects ...

Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 - Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled, "A ...

Raichur (Karnataka) [India], March 12: Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of ...

Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD). NAFLD, the most prevalent liver disease, affects ...